No 10Y consistency score yet for revenue — the window needs more comparable quarters.
Valuation vs own 10Y history: P/S N/A · No P/S — trailing revenue unavailable or non-positive.
Annualized revenue (TTM) · by quarter, last 28
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
The latest delayed quote for Greenwich LifeSciences, Inc. (GLSI) stock was $16.91 as of Oct 5, 2026, 4:00 PM EDT, down 0.41% from the previous close.
Longer view (total return, dividends reinvested): past 12 months +54.7% · 3-year avg +25.7%/yr · 5-year avg -14.8%/yr
Greenwich LifeSciences, Inc. functions as a clinical-stage biopharmaceutical company, dedicated to developing innovative cancer immunotherapies.
Biotechnology · Stafford, TX
Next Earnings Date
Nov 13, 2026
38 days away
EPS Estimate
-0.34
Revenue Est.
N/A
Last Quarter Results
EPS
$-0.27
vs Estimate
$-0.33
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1GLSI | $248.21M | $16.91 | -0.41% | +54.67% | -14.84% | N/A | N/A |
| 2IFRX | $247.45M | $1.68 | -2.33% | +6.30% | -7.34% | N/A | vs GLSI |
| 3IVVD | $247.23M | $0.84 | +2.08% | -27.54% | -51.69% | N/A | vs GLSI |
| 4GALT | $245.65M | $3.73 | -4.36% | -13.80% | +0.60% | +13.41% | vs GLSI |
| 5CAMP | $251.64M | $4.01 | +0.25% | +32.17% | N/A | N/A | vs GLSI |
| 6AKBA | $244.25M | $0.91 | +5.26% | -67.65% | -20.07% | -20.53% | vs GLSI |
forward FY estimate
N/A
$0.00
vs Estimate
$0.00
Consensus Rating
Based on 2 analysts
Average Price Target
$57.00
+237.1% upside
Low
$45.00
Current
$16.91
High
$69.00
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $-0.36 | $-0.34 | $-0.30 | 2 |
| Quarter ending Dec 2026 | $-0.40 | $-0.35 | $-0.30 | 2 |
| Quarter ending Mar 2027 | $-0.30 | $-0.30 | $-0.30 | 1 |
| Quarter ending Jun 2027 | $-0.29 | $-0.29 | $-0.29 | 1 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $-1.47 | $-1.39 | $-1.29 | 2 |
| FY 2027 | $-1.17 | $-1.17 | $-1.17 | 1 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Dec 2026 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Mar 2027 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Jun 2027 | $0.00 | $0.00 | $0.00 | 0 |
Annual
| Period | Low |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2026 | $0.00 | $0.00 | $0.00 | 0 |
| FY 2027 | $8.75M | $8.75M | $8.75M | 1 |
